N-acetyltransferase 10 (NAT10) is a dual-function nucleolar enzyme possessing both lysine acetyltransferase (KAT) and RNA cytidine acetyltransferase activities. As the sole known writer of N4-acetylcytidine (ac4C) on mRNA, tRNA, and rRNA, NAT10 has emerged as a high-value target in epitranscriptomics, oncology, and laminopathies. High-purity reagents and robust cell-based validation systems are critical for screening selective NAT10 inhibitors and dissecting its complex scaffolding functions.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NAT10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NAT10 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for biochemical assays and SPR/BLI binding studies. |
View NAT10 Products |
| Gene Delivery | NAT10 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for evaluating cellular ac4C levels and nuclear morphology rescue. |
View NAT10 Products |
| Benchmark Ab | Anti-NAT10 Recombinant Antibody Recombinant positive control for Western Blot, Immunofluorescence, and ChIP/RIP assays. |
View NAT10 Products |
| Validator | NAT10 siRNA Set For knockdown verification to confirm target specificity of small molecule inhibitors. |
View NAT10 Products |
| Related Target A | METTL3 Key RNA methyltransferase (m6A writer). Highly synergistic with NAT10 in regulating epitranscriptomic translation efficiency. |
View METTL3 Products |
| Related Target B | NPM1 Nucleolar protein interacting with NAT10. Crucial for understanding nucleolar stress responses and ribosome biogenesis. |
View NPM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity & Selectivity | Sequence-verified human recombinant NAT10 protein with preserved acetyltransferase domains. |
| Off-Target Screening | Homolog panel of related GCN5-related N-acetyltransferase (GNAT) family proteins strictly verified by mass spectrometry. |
| Lack of Controls | High-affinity recombinant benchmark antibodies included for target localization and pull-down assays. |
| False Positives in Phenotypic Screening | Validated siRNA pools included for target-specific knockdown verification in parallel with compound treatment. |
Live NAT10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NAT10 therapeutics is intensifying, with major players shifting focus from academic chemical probes to highly selective, drug-like small molecule inhibitors. Because NAT10 is an intracellular, multi-domain enzyme, therapeutic strategies primarily leverage small molecules targeting either the ATP-binding pocket or the acetyl-CoA binding site. As first-generation tool compounds like Remodelin demonstrate efficacy in preclinical cancer models and progeria, the next wave of R&D is targeting highly selective, orally bioavailable NAT10 inhibitors with improved pharmacokinetics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Storm Therapeutics, Academic Consortia | Solid Tumors (AML, Breast Cancer), Hutchinson-Gilford Progeria | Enzymatic Assay & Selectivity Screening (Need high-purity recombinant NAT10 protein) |
| PROTAC / Degraders | Biotech Startups | Refractory Cancers | Target Engagement & Degradation Kinetics (Need stable cell lines via Lentivirus) |
| Combination Therapies | Oncology Research Institutes | Chemotherapy-Resistant Tumors | Synergy Validation (Need METTL3 and NPM1 pathway proteins) |